OSR (NASDAQ:OSRH) Posts Earnings Results

OSR (NASDAQ:OSRH) announced its quarterly earnings data on Tuesday. The company reported ($0.23) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.38 million for the quarter.

OSR Price Performance

OSRH stock opened at $0.60 on Wednesday. OSR has a one year low of $0.38 and a one year high of $3.30. The stock has a market cap of $15.48 million, a price-to-earnings ratio of -0.54 and a beta of 1.54. The company has a fifty day moving average price of $0.51 and a two-hundred day moving average price of $0.59.

Institutional Trading of OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP purchased a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR as of its most recent filing with the Securities and Exchange Commission. 55.30% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a research note on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.